{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:14:55Z","timestamp":1792642495308,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.leukres.2023.107077","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T11:00:39Z","timestamp":1681470039000},"page":"107077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials"],"prefix":"10.1016","volume":"129","author":[{"given":"Wajeeha","family":"Aiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5586-6280","authenticated-orcid":false,"given":"Muhammad Ashar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdul","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimoor","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saad","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair","family":"Shafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurneel","family":"Dhanesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maroules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2023.107077_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia.","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.leukres.2023.107077_bib2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1200\/JCO.2006.10.2731","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older patients.","volume":"25","author":"Estey","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2023.107077_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27089","article-title":"Acute myelogenous leukemia in adolescents and young adults.","volume":"65","author":"Creutzig","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2023.107077_bib4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/leu.2014.216","article-title":"Management of older or unfit patients with acute myeloid leukemia","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2023.107077_bib5","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2023.107077_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.leukres.2023.107077_bib7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.31557\/APJCP.2020.21.3.721","article-title":"IDH mutations in AML patients; a higher association with intermediate risk cytogenetics.","volume":"21","author":"ElNahass","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"9","key":"10.1016\/j.leukres.2023.107077_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molmed.2010.07.002","article-title":"IDH mutations in glioma and acute myeloid leukemia.","volume":"16","author":"Dang","year":"2010","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.leukres.2023.107077_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH inhibitors in AML\u2014promise and pitfalls.","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr. Hematol. Malignan. Rep."},{"key":"10.1016\/j.leukres.2023.107077_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2023.107077_bib11","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Chandler","year":"2019"},{"key":"10.1016\/j.leukres.2023.107077_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions.","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"10.1016\/j.leukres.2023.107077_bib13","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.leukres.2023.107077_bib14","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2023.107077_bib15","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia.","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2023.107077_bib16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107077_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J."},{"issue":"13","key":"10.1016\/j.leukres.2023.107077_bib18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2023.107077_bib19","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1038\/s41375-020-0996-5","article-title":"Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.","volume":"34","author":"Heuser","year":"2020","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.leukres.2023.107077_bib20","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML.","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.leukres.2023.107077_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7006","article-title":"Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed\/refractory (R\/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial","volume":"39","author":"De Botton","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107077_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.659595","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?","volume":"12","author":"Loke","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.leukres.2023.107077_bib23","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"issue":"Suppl 2","key":"10.1016\/j.leukres.2023.107077_bib24","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/S2152-2650(22)01300-3","article-title":"AML-464 tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): phase 1b results","volume":"22","author":"Daver","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2023.107077_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107077_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-135984","article-title":"Safety and efficacy of tyrosine kinase inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of randomized clinical trials","volume":"136","author":"Fatima","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2023.107077_bib27","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML.","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107077_bib28","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial","author":"de Botton","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107077_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J."},{"issue":"18","key":"10.1016\/j.leukres.2023.107077_bib30","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia.","volume":"32","author":"Roboz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107077_bib31","article-title":"Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib\/II trial.","author":"de la Fuente","year":"2022","journal-title":"Neuro-Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2023.107077_bib32","first-page":"2536","article-title":"Ivosidenib and azacitidine in IDH1-mutated AML. Reply.","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 2","key":"10.1016\/j.leukres.2023.107077_bib33","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/S2152-2650(22)01276-9","article-title":"AML-348 a phase Ib\/II study of ivosidenib with venetoclax +\/- azacitidine in IDH1-mutated hematologic malignancies","volume":"22","author":"Lachowiez","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"22","key":"10.1016\/j.leukres.2023.107077_bib34","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:11Z","timestamp":1758935051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":34,"alternative-id":["S0145212623000620"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107077","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107077"}}